Literature DB >> 7761009

Proton magnetic resonance spectroscopy (1H-MRS) for the evaluation of treatment of brain tumours.

K Houkin1, K Kamada, Y Sawamura, Y Iwasaki, H Abe, T Kashiwaba.   

Abstract

We investigated metabolic changes in brain tumours following treatment, using proton magnetic resonance spectroscopy. In meningiomas, effective therapeutic embolisation led to an acute increase in lactate. In radiosensitive tumours such as malignant lymphoma, a decrease in lactate and in increase in N-acetyl-aspartate occurred after radiotherapy, which preceded changes observed on magnetic resonance imaging. On the other hand, no significant changes in spectral patterns were observed in malignant gliomas resistant to therapy. Tissue characterisation of brain tumours by spectral patterns on proton magnetic resonance spectroscopy remains controversial. However, we have shown it to be sensitive to metabolic changes following treatment, which may reflect the efficacy of the therapy.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7761009     DOI： 10.1007/BF00588621

Source DB:  PubMed          Journal:  Neuroradiology        ISSN： 0028-3940            Impact factor:   2.804


  13 in total

1.  Clinical application of proton magnetic resonance spectroscopy to cerebral ischemia.

Authors:  K Houkin; H Matsuzawa; M Nomura; H Saitoh; H Kamiyama; Y Iwasaki; H Abe
Journal:  Neurol Med Chir (Tokyo)       Date:  1991-07       Impact factor: 1.742

2.  Detection of metabolic heterogeneity of human intracranial tumors in vivo by 1H NMR spectroscopic imaging.

Authors:  C M Segebarth; D F Balériaux; P R Luyten; J A den Hollander
Journal:  Magn Reson Med       Date:  1990-01       Impact factor: 4.668

3.  Proton MR spectroscopy of intracranial tumours: in vivo and in vitro studies.

Authors:  S S Gill; D G Thomas; N Van Bruggen; D G Gadian; C J Peden; J D Bell; I J Cox; D K Menon; R A Iles; D J Bryant
Journal:  J Comput Assist Tomogr       Date:  1990 Jul-Aug       Impact factor: 1.826

4.  Localized 1H NMR spectroscopy in fifty cases of newly diagnosed intracranial tumors.

Authors:  P Demaerel; K Johannik; P Van Hecke; C Van Ongeval; S Verellen; G Marchal; G Wilms; C Plets; J Goffin; F Van Calenbergh
Journal:  J Comput Assist Tomogr       Date:  1991 Jan-Feb       Impact factor: 1.826

5.  Proton magnetic resonance spectroscopy of cerebral lactate and other metabolites in stroke patients.

Authors:  G D Graham; A M Blamire; A M Howseman; D L Rothman; P B Fayad; L M Brass; O A Petroff; R G Shulman; J W Prichard
Journal:  Stroke       Date:  1992-03       Impact factor: 7.914

Review 6.  A review of chemical issues in 1H NMR spectroscopy: N-acetyl-L-aspartate, creatine and choline.

Authors:  B L Miller
Journal:  NMR Biomed       Date:  1991-04       Impact factor: 4.044

7.  Regulation of hexokinase in cultured gliomas.

Authors:  J F Graham; C J Cummins; B H Smith; P L Kornblith
Journal:  Neurosurgery       Date:  1985-10       Impact factor: 4.654

8.  Persistent high lactate level as a sensitive MR spectroscopy indicator of completed infarction.

Authors:  K Houkin; I L Kwee; T Nakada
Journal:  J Neurosurg       Date:  1990-05       Impact factor: 5.115

9.  Localized proton NMR spectroscopy in different regions of the human brain in vivo. Relaxation times and concentrations of cerebral metabolites.

Authors:  J Frahm; H Bruhn; M L Gyngell; K D Merboldt; W Hänicke; R Sauter
Journal:  Magn Reson Med       Date:  1989-07       Impact factor: 4.668

10.  Noninvasive differentiation of tumors with use of localized H-1 MR spectroscopy in vivo: initial experience in patients with cerebral tumors.

Authors:  H Bruhn; J Frahm; M L Gyngell; K D Merboldt; W Hänicke; R Sauter; C Hamburger
Journal:  Radiology       Date:  1989-08       Impact factor: 11.105
View more
  9 in total

1.  Multisection 1H magnetic resonance spectroscopic imaging assessment of glioma response to chemotherapy.

Authors:  Casilda Balmaceda; Dana Critchell; Xiangling Mao; Kenneth Cheung; Susan Pannullo; Robert L DeLaPaz; Dikoma C Shungu
Journal:  J Neurooncol       Date:  2006-01       Impact factor: 4.130

Review 2.  Efficacy of proton magnetic resonance spectroscopy in neurological diagnosis and neurotherapeutic decision making.

Authors:  Alexander Lin; Brian D Ross; Kent Harris; Willis Wong
Journal:  NeuroRx       Date:  2005-04

3.  Variation of post-treatment H-MRSI choline intensity in pediatric gliomas.

Authors:  J A Lazareff; R K Gupta; J Alger
Journal:  J Neurooncol       Date:  1999-02       Impact factor: 4.130

4.  Serial proton MR spectroscopic imaging of recurrent malignant gliomas after gamma knife radiosurgery.

Authors:  E E Graves; S J Nelson; D B Vigneron; L Verhey; M McDermott; D Larson; S Chang; M D Prados; W P Dillon
Journal:  AJNR Am J Neuroradiol       Date:  2001-04       Impact factor: 3.825

5.  201Thallium SPECT and 1H-MRS compared with MRI in chemotherapy monitoring of high-grade malignant astrocytomas.

Authors:  K Kallén; I M Burtscher; S Holtås; E Ryding; I Rosén
Journal:  J Neurooncol       Date:  2000       Impact factor: 4.130

6.  Serial magnetic resonance spectroscopy reveals a direct metabolic effect of cediranib in glioblastoma.

Authors:  Heisoog Kim; Ciprian Catana; Eva-Maria Ratai; Ovidiu C Andronesi; Dominique L Jennings; Tracy T Batchelor; Rakesh K Jain; A Gregory Sorensen
Journal:  Cancer Res       Date:  2011-04-20       Impact factor: 12.701

7.  MR spectroscopy in gliomatosis cerebri.

Authors:  M Bendszus; M Warmuth-Metz; R Klein; R Burger; C Schichor; J C Tonn; L Solymosi
Journal:  AJNR Am J Neuroradiol       Date:  2000-02       Impact factor: 3.825

8.  Prognostic factors for patients with gliomatosis cerebri: retrospective analysis of 17 consecutive cases.

Authors:  Tomoo Inoue; Toshihiro Kumabe; Masayuki Kanamori; Yukihiko Sonoda; Mika Watanabe; Teiji Tominaga
Journal:  Neurosurg Rev       Date:  2011-02-08       Impact factor: 3.042

9.  A rare case of gliomatosis cerebri presenting as dementia.

Authors:  Manish Gutch; M K Ansari; Nirdesh Jain; Himanshu Yadav
Journal:  J Nat Sci Biol Med       Date:  2012-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.